Immutep share price logo

Immutep

NASDAQ: IMMP

$3.24

+0.03

(+0.93%)

Live

as on

Immutep Stock Performance

as on October 17, 2026 at 3:46 am IST

  • Day's Low

    Day's High

    $3.21
    $3.27
    downward going graph

    0.93%

    Downside

    0.93%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.36
    $70.60
    downward going graph

    -3.70%

    Downside

    2078.95%

    Upside

    downward going graph

Immutep share price movements today

Previous Close
$3.21
Open
$3.27
Volume
280.2K
Market Cap
$26.3M
Day's Low - High
$3.21 - $3.27
52 Week Low - High
$3.36 - $70.60

Immutep Historical Returns

1 Month Return
-48.83 %
3 Month Return
-61.3 %
1 Year Return
-92.03 %
3 Year Return
-90.82 %
5 Year Return
-95.72 %

Immutep Stock Fundamentals & Key Indicators

Check Immutep market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$26.3M

EPS (TTM)

-10.7

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.52

Industry PE ratio

-5.14

PEG Ratio

0.02

EBITDA

-83.4M

Revenue (TTM)

16.7M

Profit Margin

84.97%

Return On Equity TTM

-98.86%

Immutep vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immutep with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Immutep image
Immutep
Buy$26.3M-95.72%-0.5284.97%0.00%
Moderna image
Moderna
Neutral$90.3B-27.05%-29.64-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$126.4B179.89%28.7886.04%0.00%
Regeneron image
Regeneron
Buy$77.5B43.94%19.0184.86%0.48%

Stock Returns calculator for Immutep Stock including INR - Dollar returns

The Immutep stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Immutep investment value today

Current value as on today

₹8,264

Returns

-₹91,736

(-91.74%)

Returns from Immutep Stock

-₹92,358 (-92.36%)

Dollar Impact

₹622 (+0.62%)

Analyst Recommendation on Immutep Stock

Based on 9 analysts

BUY

88.89%

Buy

11.11%

Hold

0.00%

Sell

Based on 9 analysts, 88.89% of analysts recommend a 'BUY' rating for Immutep. Average target price of $30

Immutep Share Price Target

Get share price movements and forecasts by analysts on Immutep.

What analysts predicted

89.2%UPSIDE

Target Price

$30

Current Price

$3.24

Analyzed by

9 Analysts

Target

$30.00

Immutep target price $30, a slight upside of 89.2% compared to current price of $3.24. According to 9 analysts rating.

Indian Investors' Interest in Immutep Stock

Search interest for Immutep Stock has increased by 18% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:18% versus previous 30 day period

Immutep Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Jun 2024
Dec 2024
Dec 2024
Jun 2025
Jun 2025
Dec 2025
Dec 2025
Jun 2026
Jun 2026
Total Revenue
1
1
3
3
1
1
6
6
10
10
Gross Profit
-19
-19
-22
-22
-34
-34
-40
-40
9
9
Operating Income
-44
-44
-51
-51
-74
-74
-46
-46
-39
-39
EBITDA
-22
-22
-26
-26
-36
-37
-44
-44
-38
-38
Interest Expense
0
0
-
-
-
-
0
0
0
0
Depreciation
1
1
0
0
2
1
1
1
1
1
Income Before Tax
-21
-21
-22
-22
-39
-39
-44
-44
-34
-34
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-21
-21
-22
-22
-39
-39
-44
-44
-34
-34
Net Profit Margin
-1119.45%
-1119.45%
-704.74%
-704.74%
-1802.84%
-1802.84%
-673.61%
-673.61%
89.89%
89.89%

Immutep Annual Profit & Loss

All numbers in Millions USD

Jun 2022
Jun 2022
Jun 2023
Jun 2023
Jun 2024
Jun 2024
Jun 2025
Jun 2025
Jun 2026
Jun 2026
Total Revenue
0
0
3
3
3
3
5
5
14
14
Gross Profit
-1
-1
1
1
-37
-37
-56
-56
11
11
Operating Income
-33
-33
-77
-77
-88
-88
-126
-126
-82
-82
EBITDA
-31
-31
-39
-39
-44
-44
-62
-62
-79
-79
Interest Expense
0
0
0
0
0
0
-
-
0
0
Depreciation
1
2
1
2
2
2
2
2
2
2
Income Before Tax
-32
-32
-39
-39
-42
-42
-61
-61
-77
-77
Income Tax Expense
0
0
-
-
-
-
-
-
-
-
Net Income
-32
-32
-39
-39
-42
-42
-61
-61
-77
-77
Net Profit Margin
-1111.18%
-1111.18%
41.19%
41.19%
-981.42%
-981.42%
-1117.55%
-1117.55%
83.01%
83.01%

Immutep Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Jun 2024
Dec 2024
Dec 2024
Jun 2025
Jun 2025
Dec 2025
Dec 2025
Jun 2026
Jun 2026
Net Income
-21
-21
-22
-22
-39
-39
-44
-44
-34
-34
Operating Cash Flow
-17
-17
-28
-28
-33
-33
-28
-28
-29
-29
Investing Cash Flow
-20
-20
-30
-30
24
24
34
34
23
23
Financing Cash Flow
95
95
0
0
0
0
0
0
0
0
Change in Cash
66
66
-46
-46
-73
-73
6
6
-1
-1

Immutep Annual Cash Flow

All numbers in Millions USD

Jun 2022
Jun 2022
Jun 2023
Jun 2023
Jun 2024
Jun 2024
Jun 2025
Jun 2025
Jun 2026
Jun 2026
Net Income
-32
-32
-39
-39
-42
-42
-61
-61
-77
-77
Operating Cash Flow
-30
-30
-35
-35
-34
-34
-62
-62
-54
-54
Investing Cash Flow
0
0
0
0
-21
-21
-38
-38
55
55
Financing Cash Flow
50
50
76
76
95
95
0
0
0
0
Change in Cash
19
19
43
43
38
38
-94
-94
5
5

Global Institutional Holdings in Immutep

Check out the Institutions with significant holdings in Immutep.

Funds
Holdings
iShares
0.53%
Fidelity Concord Street Trust
0.01%
DFA INVESTMENT DIMENSIONS GROUP INC
0.01%
iShares
0.55%
Fidelity Concord Street Trust
0.25%
See all

Immutep News & Key Events

  • img

    Today's Timeline - 22 September

    Tue, 03:31 PM

    -

    Immutep announces a 1-for-20 reverse split of ADSs effective September 28, 2026, to regain Nasdaq compliance.

Insights on Immutep

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 1.89M → 10.62M (in $), with an average increase of 55.9% per quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -44.85M → -34.93M (in $), with an average increase of 28.4% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 157.2% return, outperforming this stock by 248.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 771.4% return, outperforming this stock by 863.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, IMMP stock has moved down by -50.9%

About Immutep

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
OrganisationImmutep
HeadquartersAustralia Square, Sydney, NSW, 2000, AU
IndustryBiotechnology
CEOMarc Voigt

Key Management of Immutep

Name

Title

Mr. Marc Voigt

CEO, MD, CFO, Chief Business Officer & Executive Director

Ms. Deanne Miller LLB

COO, General Counsel & Joint Company Secretary

Dr. Frederic Triebel M.D., Ph.D.

Chief Scientific Officer & Executive Director

Mr. Christian Mueller BBA, MSc.

Chief Development Officer

Dr. Stephan Winckels M.D., Ph.D.

Chief Medical Officer

Ms. Indira Naidu

Joint Company Secretary

FAQs

What is Immutep share price today?

Immutep share price today is $3.24 as on . Immutep share today touched a day high of $3.27 and a low of $3.21.

What is the 52 week high and 52 week low for Immutep share?

Immutep share touched a 52 week high of $70.60 on and a 52 week low of $3.36 on . Immutep stock price today i.e. is trending at $3.24,which is 95.41% down from its 52 week high and -3.57% up from its 52 week low.

What is Immutep's market capitalisation today?

Immutep market capitalisation is $0.00T as on .

How to invest in Immutep Stock (IMMP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Immutep on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Immutep Stock (IMMP) from India?

Indian investors can start investing in Immutep (IMMP) shares with as little as ₹94.95999908447266 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.60 in Immutep stock (as per the Rupee-Dollar exchange rate as on ). Based on Immutep share’s latest price of $3.24 as on October 16, 2026 at 10:16 pm IST, you will get 3.0864 shares of Immutep. Learn more about fractional shares .

What are the returns that Immutep has given to Indian investors in the last 5 years?

Immutep stock has given -95.72% share price returns and 27.65% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?